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a b s t r a c t
There is a need to improve the efficacy of the BCG vaccine against human and bovine tuberculosis.
Previous data showed that boosting bacilli Calmette-Guerin (BCG)-vaccinated cattle with a recombinant
attenuated human type 5 adenovirally vectored subunit vaccine (Ad5-85A) increased BCG protection and
was associated with increased frequency of Ag85A-specific CD4+ T cells post-boosting. Here, the capacity
of Ag85A-specific CD4+ T cell lines – derived before and after viral boosting – to interact with BCG-
infected macrophages was evaluated. No difference before and after boosting was found in the capacity
of these Ag85A-specific CD4+ T cell lines to restrict mycobacterial growth, but the secretion of IL-10
in vitro post-boost increased significantly. Furthermore, cell lines derived post-boost had no statistically
significant difference in the secretion of pro-inflammatory cytokines (IL-1b, IL-12, IFNc or TNFa) com-
pared to pre-boost lines. In conclusion, the protection associated with the increased number of Ag85A-
specific CD4+ T cells restricting mycobacterial growth may be associated with anti-inflammatory proper-
ties to limit immune-pathology.
 2018 Department for Environment Food and Rural Affairs. Published by Elsevier Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Bovine tuberculosis (bTB), caused mainly by Mycobacterium
bovis, poses economical, animal welfare and human health prob-
lems [1]. Development of vaccines for cattle, to be used in conjunc-
tion with current regulations, is part of control and eradication
strategies for England and Wales for controlling bTB [2,3].
Cattle vaccinated with the live attenuated M. bovis bacillus
Calmette-Guerin (BCG) and boosted with adenovirus type 5 (Ad5)
expressing Mycobacterium tuberculosis Ag85A (Ag85A) (Ad5-
Ag85A) showed improved protection against pathology associated
with M. bovis [4,5]. Recently, we adapted the use of the antigen-
unbiasedT cell expansionmethod fromGeiger et al. [6] to the bovine
system[7]. This approachavoids initial in vitrobias causedbyexpan-
sion of T cell lines by specific repeated cycles of antigen stimulation.
We reported that boosting BCG-vaccinated cattle with Ad5-85A
increased the frequency of Ag85A-specific CD4+ T cell lines, which
correlatedwithprotection, but therewas no change in T-cell antigen
avidity or epitope-recognition repertoire; the avidity of Ag-85A
specific CD4+ T cells was not modulated by viral boosting [7].
Therefore, it was of interest to further characterise the functional
properties of these Ag85A-specific CD4+ T cell lines derived from
BCG-primed and Ad5-85A-boosted cattle.
In this study, the capacity of these Ag85A-specific CD4+ T cells –
generated either before or after Ad-85A boost – to control
mycobacteria in vitro and their cytokine profile, after culture for
24 h with BCG-infected macrophages, have been evaluated. Our
data suggest that boosting BCG with Ad5-85A enhances protection
by increasing the number of Ag85A-specific CD4+ T cells capable of
controlling mycobacteria, whilst also potentially developing anti-
inflammatory properties to limit immune-pathology.
2. Materials and methods
2.1. Animals
Experiments were carried out according to the UK Animal
(Scientific Procedures) Act 1986 under project license
PPL70/7737. The study protocol was approved by the APHA Animal
https://doi.org/10.1016/j.vaccine.2018.03.068
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Use Ethics Committee (UK Home Office PCD number70/6905) and
has been reported previously [5]. Briefly, all animals were
vaccinated with 1  106 Colony Forming Units (CFU) M. bovis
BCG Danish 1331 subcutaneously at week (wk) 0; Ad5-85A
boosted cattle were inoculated at wk 8 with 2  109 infectious
units of Ad5-85A by intradermal injection on the shoulder; all ani-
mals were challenged endobronchially with 2  103 CFU M. bovis
AF2122/97 strain at wk 12 [5]. Peripheral blood mononuclear cells
(PBMC) were cryo-preserved pre- (wk 8) and post-boost (wk 11)
and used to generate CD4+ T cell lines. The present study utilised
Ag85A-specific CD4+ T cell lines, from three BCG-primed Ad5-
85A-boosted cattle and one BCG-vaccinated control, acquired in
the study described previously [7]. Thirteen pre-boost cell lines
were used from two animals (three from one animal and ten from
the BCG control) and thirteen post-boost cell lines were used from
three animals (five from one animal and four from each of the
remaining animals).
2.2. Isolation and selection of pre-/post- boost Ag85A-specific CD4+ T
cell lines
Polyclonal CD4+ T cell libraries were generated from pre-boost
(wk 8) and post-boost (wk 11) PBMC using a method adapted from
Geiger et al. [6], as described previously [7]. Ag85A-specific CD4+ T
cells were identified by screening the different polyclonal cell
cultures for their capacity to proliferate using 1  105  2  105
CD4+ T cells per culture and 5 mg/ml (initial screening) or 10 mg/
ml (subsequent screening) recombinant Ag85A (Lionex GmbH,
Germany) and 5  103 CD14+ as antigen presenting cells per well
of 96-well U-bottom plates. Ag85A-specific CD4+ T cell lines were
expanded, after each 11 day Ag85A-selective culture, using 1 mg/
ml lectin from Phaseolus vulgaris leucoagglutinin PHA-L (PHA –
Sigma-Aldrich) in the presence of 10 U/ml recombinant human
interleukin 2 (Gentaur, Belgium) and CD14+ feeder cells for nine
days and cryopreserved. All Ag85A-specific CD4+ T cell lines used
in these experiments had undergone three sequential rounds of
Ag85A-PHA stimulation.
2.3. Bovine monocyte/macrophage cell culture
Autologous bovine CD14+ (monocytes) or granulocyte-
macrophage colony stimulating factor (GM-CSF)-matured CD14+
cells (macrophages [Mu]) were cultured at 37 C (5% CO2) in com-
plete medium consisting of RPMI 1640 containing 2 mM GlutaMax,
25 mM HEPES, 0.1 mM non-essential amino acids, 5  105 M b-
mercaptoethanol, 50 mg/ml Gentamicin (all from Life Technologies,
UK), and 10% foetal calf serum (FCS) (Sigma-Aldrich, UK) (complete
medium). For Mu differentiation, monocytes were cultured at a
density of 1  106/ml in medium containing recombinant bovine
GM-CSF diluted 1/100 (Bio-rad, UK) for six days in Corning Ultra-
low adhesion flasks (Sigma-Aldrich); cells were fed GM-CSF on
day three. After six days, Mu were harvested by incubating flasks
Fig. 1. Characterisation of CD14+cell-derived mature macrophage phenotype. Representative plots of CD14+ cells matured into macrophages (Mu) by culturing in medium
supplemented with GM-CSF for six days as described in materials and methods. Harvested Mu were selected based on their large FSC/SSC phenotype and live Mu were
analysed for CD11c, CD11b and MHC class II (DQ) as described. Plots shown were derived from GM-CSF-matured CD14+ obtained from a cow infected naturally withM. bovis
that was used to develop the methodology.
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in ice for 20–30 min and washed. Fig. 1 shows a representative
immune phenotype profile of GM-CSF matured cells, which defines
their surface phenotype as CD11b+CD11c+BoLA-DQ+, which is con-
sistent with GM-CSF matured CD14+/bone-marrow-derived cells
[8,9]). Mu were labelled with the following murine monoclonal
antibodies (mab): mAb CC158 (Bio-rad), against bovine MHC class
II (DQ), conjugated to Fluorescein using the Lightning Link kit
(Innova Biosciences, UK); IL-A16 (a kind gift from Dr Jan Naessens,
ILRI, Nairobi, Kenya) against bovine CD11c, conjugated to R-
Phycoerythrin using the Zenon labelling kit (Life Technologies);
and mAb CC94, to bovine CD11b, conjugated to Alexa Fluor 700
using the Zenon labelling kit (Life Technologies). Labelled cells
were acquired in a CyAn ADP cytometer (Beckman Coulter, UK)
using Summit 4.3 (Beckman Coulter) and analysed with FlowJo
7.6.5 (TreeStar, USA). Live cells for analysis were selected based
on their FSC/SSC profile and stain pattern with LIVE/DEAD Fixable
Violet Dead Cell Stain (Life technologies).
2.4. BCG-activation of Ag85A-specific CD4± T cells
BCG Tokyo (a kind gift from Dr M. Behr, McGill University,
Canada) was grown as described previously [10]. Prior experiments
had indicated that transcription of potentially cytotoxic genes by
antigen-specific stimulated CD4+ T-cells occurs at six days after
stimulation. Therefore, CD4+ T-cells were stimulated as previously
described [13] with small modifications; briefly, monocytes seeded
in 24-well plates at a density of 2.5  105/ml (1 ml/well), were
infected with BCG Tokyo in antibiotic-free medium at a ratio of
4:1 BCG:monocytes. After 16 h, 1 ml of 7.5  105 Ag85A-specific
CD4+ T cells in complete medium were added to BCG-infected
monocytes. Cultures were fed with 10 U/ml IL-2 on day four
and used for evaluation of mycobacterial growth inhibition on
day six.
2.5. Evaluation of mycobacterial growth inhibition
BCG has been established as an accepted microorganism for the
evaluation of mycobacterial growth [11,12]. Prior to infection with
BCG, Mu were washed in antibiotic-free medium. 2  105 Mu per
ml were infected with BCG Tokyo in antibiotic-free medium at a
BCG:Mu ratio of 5:1 in 48-well plates (0.5 ml/well). After 16 h,
wells containing BCG-infected Mu were washed thrice with 0.5
ml HBSS (Gibco) and co-cultured for 24 h with BCG-activated
CD4+ T cells, at a density of 8  105 cells/ml in a final volume of
0.5 ml of medium containing 50 mg/ml gentamicin; control wells
contained infected Mu but no CD4+ T cells. Supernatants were cry-
opreserved for analysis and cells were incubated with 0.55 ml/well
sterile deionised H2O on ice for 30 mins and disrupted by pipet-
ting; 0.5 ml/well of homogenate was transferred to Mycobacteria
Growth Indicator tubes (MGIT) containing 7 ml BBL MGIT broth
and 0.8 ml BACTEC MGIT Growth Supplement/BBL MGIT PANTA
antibiotic mixture and incubated in a BACTEC MGIT 320 reader
(Becton, Dickinson and Company, USA). CFU were calculated using
the time to positivity against a BCG Tokyo growth curve. Reduction
in BCG CFU was calculated relative to the medium culture control
for each animal.
2.6. Analysis of cytokine secretion
Supernatants from the mycobacterial growth inhibition experi-
ments were analysed for IFN-c secretion using the BovigamTM assay
kit (Prionics AG, Switzerland); IL-1b, IL-10, TNF-a and IL-12 were
evaluated using a MULTI-SPOT 96-Well – 7 Spot plate kit (Meso
Scale Discovery (MSD), USA) (IL-10 and IL-12 were a kind gift from
Dr J. Hope, then at the Institute for Animal Health, Compton). Con-
centrations for cytokines were derived from standard curves of
recombinant bovine cytokines after subtracting animal-specific
background in BCG-infected macrophages.
2.7. Gene transcription assays
RNA was prepared from Ag85A-specific CD4+ T cell lines at days
zero and six after BCG-activation, using TRIzol (Ambion, Life Tech-
nologies) and RNeasy kits (Qiagen, UK) according to the manufac-
turers’ instructions. Due to restrictions in the number of cells
available for each cell line, it was possible to carry out transcription
analysis for six pre-boost cell lines derived from two animals (two
from one animal and four from the other) and for four post-boost
cell lines derived from three animals (two from one animal and
one from each of the remaining animals). cDNA was synthesised
from 100 ng total RNA using SuperScript VILO cDNA synthesis kits
(Invitrogen) and a GeneAmp PCR System 9700 (Applied Biosys-
tems) at 42 C for 1 h and 85 C for 5 min. Bovine perforin, gran-
ulysin, granzyme A and GAPDH gene transcription were detected
using 2 ml of the cDNA template and 1 ml Taqman Gene expression
Assay (20x) primer in a 20 ml Taqman Fast Advanced Mastermix
Real-Time PCR reaction (Applied Biosystems, UK) using a ViiA
Real-time PCR System (2 min 50 C hold, 20 sec 95 C hold, 40
cycles of 1 sec 95 C denature and 20 sec anneal/extend). Relative
BCG-stimulated gene trasncription was determined using the
DDCt method with GAPDH as the reference gene. Data shown
are for day six relative to day zero. Taqman assay reference codes
for bovine perforin, granulysin, granzyme A and GAPDH are pro-
vided in Table 1 (Thermo Fisher).
2.8. Statistics
Data analysis was performed using GraphPad Prism version 7
(GraphPad Software, La Jolla, CA, USA). Comparisons were made
using the unpaired two-tailed t-test with significance level set at
5%.
3. Results
Ag85A-specific CD4+ T cell lines derived from BCG-vaccinated
cattle, before and after boosting with Ad5-85A (generated and
cyro-preserved in a previous study [7]), were evaluated for recog-
nition of BCG-infected autologous Mu in a 24 h co-culture system
adapted from Endsley et al. [13]. Mycobacterial growth inhibition
was assessed by determining the reduction of BCG load after co-
culture (Fig. 2A). No difference in the ability to inhibit mycobacte-
rial growth was found between Ag85A-specific CD4+ T cells lines
obtained prior to and after boost, suggesting that boosting BCG-
vaccinated cattle with Ad5-85A does not increase the anti-
mycobacterial capacity of Ag85A-specific CD4+ T cells. Similarly,
no statistically significant differences were found in the secretion
of the pro-inflammatory cytokines IL-1b, IL-12, IFN-c and TNF-a
(Fig. 2B–E) between cultures containing pre-boost and post-boost
Ag85A-specific CD4+ T cells. Nevertheless, there were common
trends towards lower amounts of pro-inflammatory cytokines in
post-boost cultures. In contrast, we observed a statistically signif-
Table 1
ThermoFisher RT-PCR Taqman assay kit reference codes.
Perforin Bt03816262_m1
Granulysin Bt03287460_g1
Granzyme Bt03271024_m1
GAPDH Bt03210914_g1
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icant increase in IL-10 secretion in the cultures containing Ag85A-
specific CD4+ T cells obtained post-boost (Fig. 2F) compared to the
IL-10 levels induced in Ag85A-specific CD4+ T cells obtained pre-
boost.
The observed lack of difference in anti-mycobacterial capacity
of Ag85A-specific CD4+ T cell lines ex vivo is consistent with com-
parable pre- and post-boost transcription of effector molecules
thought to be involved in the killing of mycobacteria, (perforin,
granulysin and granzyme A, [Fig. 3]).
4. Discussion
In this study, boosting BCG vaccinated cattle with Ad5-85A did
not induce significant differences in Ag85A-specific CD4+ T cell
lines obtained post-boost compared to cell lines obtained prior to
boosting in terms of secretion of pro-inflammatory cytokines, tran-
scription of molecules associated with cytotoxicity, or control of
mycobacteria. However, Ag85A-specific CD4+ T cell lines obtained
post-boost secreted more of the immune regulatory cytokine IL-
10 than CD4+ T cell lines obtained prior to viral boosting.
It has been proposed that the induction of robust Th1 responses
is a strategy employed by mycobacteria to facilitate its multiplica-
tion and dissemination [14–18]. More recently, Moguche et al. [19]
showed in mice that continuous expression of ESAT-6 drives the
expansion and maintenance of ESAT-6 specific T-cells. This
continuous expansion resulted in large numbers of terminally dif-
ferentiated ESAT-6 specific T-cells with limited protective capacity.
In contrast, expression of Ag85 is limited to the early stages of
infection, resulting in the priming of Ag85A/Ag85B specific
memory T-cells which, although functional, are reduced in num-
bers due to the limited amount of Ag85A present during infection
in later stages of infection.
Fig. 2. Comparison of the anti-mycobacterial capacity and cytokine response of activated Ag85A-specific CD4+ T cell lines derived from BCG-primed Ad5-85A-boosted cattle.
Ag85A-specific CD4+ T cell lines derived from BCG-vaccinated cattle, both pre- and post- boosting with Ad5-85A, were stimulated with BCG-infected monocytes for six days
and co-cultured for 24 h with BCG-infected Mu as described. The percentage reduction in BCG load (A) was analysed as described in materials and methods, together with
cytokine secretion: IL-1b (B), IL-12 (C), IFN-c (D), TNF-a (E) and IL-10 (F). The thirteen pre-boost cell lines were derived from two animals (three from one animal and ten from
a BCG control) and the thirteen post-boost cell lines were derived from three animals (four from one animal and five from each of the remaining animals). Statistical
comparisons were made using the unpaired t-test.
Fig. 3. Evaluation of transcription of cytotoxic genes in BCG-activated
Ag85A-specific CD4+ T cell lines derived from BCG-primed Ad5-85A boosted cattle.
Ag85A-specific CD4+ T cell lines derived from BCG-vaccinated cattle, both pre- and
post- boosting with Ad5-85A, were activated with BCG-infected CD14+ cells for six
days as described in materials andmethods. RNAwas extracted from Ag85A-specific
CD4+ T cells at day zero and day six after BCG-stimulation and analysed for bovine
perforin, granulysin and granzyme A gene expression. Due to restrictions in the
number of cells available for each cell line, it was possible to carry out transcription
analysis for six pre-boost cell lines derived from two animals (two from one animal
and four from the other) and for four post-boost cell lines derived from three animals
(two from one animal and one from each of the remaining animals). Data shown are
for transcription observed at day six relative to transcription observed at day zero.
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It is likely that the level of protection observed in BCG vacci-
nated and Ad5-85A boosted cattle was in part due to the expansion
of the pool of cells specific for Ag85A [7]. This increase in the num-
ber of functionally active Ag85A-specific T-cells prior to infection
enabled Ag85A to be detected early during infection, when
Ag85A is more likely to be expressed by mycobacteria. Thus, we
speculate that it is the availability of a greater number of Ag85A-
specific CD4+T-cells, induced by boosting (as previously shown
[7]), which led to a greater control of mycobacteria (rather than
any enhancement in anti-mycrobacterial mechanisms which we
did not detect). However, the control of mycobacteria by Ag85A-
specific CD4+ T-cells appears to be accompanied by the production
of IL-10; this is somewhat surprising as IL-10 has been associated
with a decrease in protection against mycobacteria [20,21]. On the
other hand IL-10 is an immune-regulatory/anti-inflammatory
cytokine that contributes to the control of IFNc responses which,
whilst necessary for protection against mycobacteria, have been
positively associated with pathology induced by M. bovis [22]. In
this work the selection of CD4+ cells was based on their prolifera-
tive response, first in an unbiased manner by stimulation with PHA
and then in an antigen specific manner by stimulation with Ag85A.
It has been shown that cells detected in proliferative assays, such
as the one used in this work, do not necessarily correlate with
other types of assays such as those detecting production of IFNc
(Steinbach, S. et al unpublished observation). Thus it is possible
that protection induced by Ad5-Ag85A may be the result of the
induction of two functionally different Ag85A-specific CD4+ T-cell
populations; one population producing inflammatory cytokines,
which were able to control, directly or indirectly, mycobacteria;
and one population producing IL-10, with anti-inflammatory prop-
erties capable of controlling pathology. Successful vaccination
against mycobacteria requires the control of the pathogen and of
the detrimental immune response induced by the pathogen. The
data obtained from these experiments contribute to our
understanding of the nature of the immune response required for
protection against tuberculosis in cattle. This information is
required for the formulation of more rationally designed vaccines
capable of inducing protective immune responses whilst avoiding
the induction of pathogenic immune responses.
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